Current state of the art technologies for CNS disease mechanism studies and drug discovery include rodent models. These models are failing in their predictive capacity in translational medicine applications. Our proprietary human neural organoid models yield clinically corroborated results of opioid use disorders and novel therapeutic drugs identified.
Primary Application Area: Biotech, Pharma, Health
Technology Development Status: Commercial Product
Technology Readiness Level: TRL 7
Vetted Programs/Awards: SBIRs
Organization Type: Mid-stage Startup (A or B)
Showcase Booth: 524T
Market Keywords: Diagnostics, Therapeutics, Addiction